Sugi Predict

Sugi Predict / Compounds / SCHEMBL401273

SCHEMBL401273

SCHEMBL401273

CC(C)OC(=O)N1CCN(Cc2ccc(F)c(NC(=O)Nc3ccc(C#N)nc3)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 6/20 0.46
▸ KCNQ3 O43525 1/20 0.43
▸ KCNQ2 O43526 1/20 0.43
▸ PRKAA2 P54646 2/20 0.39
▸ FAAH O00519 3/20 0.39
▸ MAP3K11 Q16584 1/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ NAMPT P43490 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ GPR6 P46095 2/20 0.37
▸ PLA2G7 Q13093 1/20 0.37
▸ MGLL Q99685 1/20 0.37
▸ ABHD6 Q9BV23 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL402283 0.93 CHEK1 (0.51) CHEK1KCNQ3KCNQ2PRKAA2FAAH
SCHEMBL402565 0.90 CHEK1 (0.47) CHEK1KCNQ3KCNQ2NPC1RAB9A
SCHEMBL402016 0.89 CHEK1 (0.48) CHEK1KCNQ3KCNQ2PRKAA2FAAH
SCHEMBL400430 0.88 KCNQ3 (0.41) KCNQ3KCNQ2PRKAA2FAAHMAP3K11
SCHEMBL401274 0.88 CHEK1 (0.45) CHEK1KCNQ3KCNQ2PRKAA2FAAH
SCHEMBL3198406 0.87 CHEK1 (0.46) CHEK1KCNQ3KCNQ2PRKAA2FAAH
SCHEMBL402376 0.87 PRKAA2 (0.40) CHEK1KCNQ3KCNQ2PRKAA2FAAH
SCHEMBL401895 0.87 PRKAA2 (0.43) PRKAA2FAAHMAP3K11NPC1RAB9A
SCHEMBL29714042 0.80 RAB9A (0.45) KCNQ3KCNQ2PRKAA2FAAHNPC1
SCHEMBL400815 0.80 RAB9A (0.45) KCNQ3KCNQ2PRKAA2FAAHNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US claimed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US claimed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US claimed
EP-2862859-A2 Compounds, compositions and methods Cytokinetics, Inc. (US) 2015-04-22 — — EP claimed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US claimed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US claimed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US claimed
US-12264133-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2025-04-01 — — US disclosed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
EP-1765327-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2007-03-28 — — EP disclosed
WO-2006009726-A2 SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES CYTOKINETICS, INC. (US) 2006-01-26 — — WO disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 CHEK1 1935/4885KCNQ3 3060/4885KCNQ2 2435/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 CHEK1 2918/4885KCNQ3 3612/4885KCNQ2 3389/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 CHEK1 2194/4885KCNQ3 3001/4885KCNQ2 2819/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 CHEK1 2194/4885KCNQ3 3001/4885KCNQ2 2819/4885
US-12264133-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 CHEK1 2194/4885KCNQ3 3001/4885KCNQ2 2819/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 CHEK1 2194/4885KCNQ3 3001/4885KCNQ2 2819/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 CHEK1 2194/4885KCNQ3 3001/4885KCNQ2 2819/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 CHEK1 2194/4885KCNQ3 3001/4885KCNQ2 2819/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 CHEK1 2194/4885KCNQ3 3001/4885KCNQ2 2819/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 CHEK1 2194/4885KCNQ3 3001/4885KCNQ2 2819/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 CHEK1 2194/4885KCNQ3 3001/4885KCNQ2 2819/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 CHEK1 2194/4885KCNQ3 3001/4885KCNQ2 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.